Ipsen (IPSEF) ROCE %: 6.69% (As of Dec. 2025)


IPSEF Ipsen SA IPSEF
95 GF Score
Price $113.13
GF Value $92.81
! 7 Warning Signs
View Full Analysis

What is Ipsen ROCE %?

Ipsen IPSEF 95 ROCE % is 6.69% as of Dec. 2025. GuruFocus rates IPSEF with a GF Score™ of 95/100 and a GF Value™ of $92.81. The stock has 7 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Ipsen's annualized ROCE % for the quarter that ended in Dec. 2025 was 6.69%.

Ipsen  (OTCPK:IPSEF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Ipsen ROCE % Related Terms

Ipsen ROCE % Historical Data

* Premium members only.

The historical data trend for Ipsen's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ipsen ROCE % Chart

Ipsen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.90 17.77 18.06 9.64 12.57

Ipsen Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23.10 12.47 6.95 17.86 6.69
IPSEF
95GF Score
Ipsen SA IPSEF
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ipsen ROCE % Calculation

Ipsen's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=729.391/( ( (6742.408 - 1576.335) + (8123.888 - 1686.066) )/ 2 )
=729.391/( (5166.073+6437.822)/ 2 )
=729.391/5801.9475
=12.57 %

Ipsen's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=424.356/( ( (7878.316 - 1636.217) + (8123.888 - 1686.066) )/ 2 )
=424.356/( ( 6242.099 + 6437.822 )/ 2 )
=424.356/6339.9605
=6.69 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 6.69% mean?
Ipsen (IPSEF) has a ROCE % of 6.69% as of Dec. 2025.
Is Ipsen's ROCE % too high?
Ipsen's current ROCE % is 6.69%. The Drug Manufacturers industry median ROCE % is 7.00. Ipsen's value of 6.69% is 4.4% below this industry median. Overall, Ipsen has a GF Score™ of 95/100, reflecting its overall financial health beyond just this single metric.
How does Ipsen's ROCE % compare to ZTS and UTHR?
Ipsen's ROCE % of 6.69% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.00. Ipsen's value of 6.69% is 4.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.00, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ipsen's current ROCE % of 6.69% is 4.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ipsen's current ROCE % is 6.69%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ipsen stock overvalued right now?
Ipsen (IPSEF) has a current ROCE % of 6.69%. The stock's GF Value™ is $92.81, compared to a current price of $113.13 — trading 21.9% above its estimated fair value. The current ROCE % is 6.69% and 4.4% below the Drug Manufacturers industry median of 7.00. Ipsen's overall GF Score™ is 95/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Ipsen (IPSEF), the current ROCE % is 6.69% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ipsen (IPSEF) Overvalued in 2026?

Based on GuruFocus' analysis, Ipsen stock appears to be overvalued. The current stock price of $113.13 is trading 21.9% above its estimated GF Value™ of $92.81.

Key valuation signals for IPSEF:

  • ROCE %: 6.69%
  • GF Value™: $92.81 vs. price of $113.13 (21.9% above fair value)
  • GF Score™: 95/100 with 7 warning signs
  • Industry Position: 4.4% below the Drug Manufacturers median

No single metric tells the full story. See the IPSEF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ipsen Business Description

Address 70 rue Balard, Paris, FRA, 75015
Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was founded in 1929 as a consumer healthcare company focused on prescription-based products for digestive disorders and neurological disorders, but in February 2022, Ipsen announced the divestment of its consumer healthcare business, which accounted for only 8% of 2021 revenue. Ipsen has a large global footprint and sells more than 20 drugs in 115 countries.
95GF Score

Get the complete analysis for IPSEF

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$113.13
Price
$92.81
GF Value